Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Press releases
June 8, 2022
François Fournier as new CEO
Javené, June 8th, 2022 –
An experienced healthcare executive and expert in HTL’s therapeutic areas, in particular dermatology and medical aesthetics, François Fournier brings more than 20 years’ experience in corporate strategy, business execution, and international leadership.
Prior to joining HTL, François Fournier, of French and American nationality, worked in many
countries and several continents in different management positions at pharmaceutical companies,
including most recently at Virbac (as president and CEO of Virbac North America based in Dallas) and previously at Smith & Nephew and Galderma.
Read more below
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Press releases June 5, 2025HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
-
Press releases May 27, 2025HTL Biotechnology supports National Biomedicines manufacturing Day
HTL Biotechnology is proud to support National Biomedicines manufacturing Day, which will take place on June 5, 2025.
-
Articles April 2, 2025François Fournier Featured in Korean Press
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.